Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hypertension
Interventions: CIN-107, Matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Hypertension
Interventions: CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Hypertension
Interventions: Metformin, CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: baxdrostat (formerly CIN-107) oral solution; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 2 more

Conditions: Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions: AZD4635, Durvalumab, Cabazitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Heart Failure, Cardiovascular Diseases
Interventions: NT-proBNP; Diagnostic Test
Lead sponsor: NHS Greater Glasgow and Clyde; Other
Eligibility: 40 Years and older
Enrollment: 3,904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
Interventions: AZD0466; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more

Conditions: Colorectal Cancer
Interventions: Amifostine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Dapagliflozin, Exenatide, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

Baxdrostat Bioavailability and Bioequivalence Study

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

About this AstraZeneca sponsor directory page